

# ANCO FAX News

Association of Northern California Oncologists  
Post Office Box 151109, San Rafael, California 94915-1109  
Voice: (415) 472-3960 • FAX: (415) 472-3961  
[execdir@anco-online.org](mailto:execdir@anco-online.org) • [www.anco-online.org](http://www.anco-online.org)

Vol. 16, No. 11

June 9<sup>th</sup>, 2017

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association* and membership news. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at [www.anco-online.org/pubs.html](http://www.anco-online.org/pubs.html).

#### In this issue:

- ASCO & ASH comment on proposed *Federal* budget
- ANCO's *The State of Cancer Care* at ASCO's *Best of ASCO*
- *JOP* article on Advanced Care Planning

**The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts) Members.** The next regular *ANCO FAX News* will be published on June 23<sup>rd</sup>. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; [execdir@anco-online.org](mailto:execdir@anco-online.org).

**The *ANCO FAX News* has information for every member of your practice or organization. Pass it along!**

- Physician Members
- Nurses & Office Managers
- Office Staff
- Colleagues & Representatives

The *Association of Northern California Oncologists* (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge. The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

## ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

### **ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues**

ASCO and ASH have issued statements strongly opposing the Trump *Administration's* proposed cuts to *Federal* agencies that support biomedical research and Medicaid for FY2018, including a 21% proposed funding cut for NIH, a 20% proposed funding cut for NCI, and reducing Medicaid funding by more than \$600B. Such extreme reductions to programs that are critical to research will fundamentally damage the nation's progress in treating patients and will irreversibly harm the nation's already fragile biomedical research infrastructure.

CMS is readying a fraud prevention initiative that removes *Social Security Numbers* from Medicare cards to help combat identity theft and safeguard taxpayer dollars. The new cards will use a unique, randomly-assigned number called a *Medicare Beneficiary Identifier* (MBI) to replace the *Social Security-based Health Insurance Claim Number* (HICN) currently used on the Medicare card. CMS will begin mailing new cards in April 2018. For more information, visit the CMS *Social Security Removal Initiative* (SSNRI) website at [www.cms.gov/medicare/ssnri/](http://www.cms.gov/medicare/ssnri/).

The *Medicare Quality Payment Program* (QPP), established by the *Medicare Access and CHIP Reauthorization Act* (MACRA), began on January 1<sup>st</sup>. This year is a transition year meaning you can "pick your pace" when implementing QPP in your practice. CMS has posted new resources to the QPP website to help clinicians successfully participate in the first year of the QPP. The new

resources focus on support for small practices and alternative payment models (APMs). Visit [qpp.cms.gov](http://qpp.cms.gov) for more information.

### **Unsure of your MIPS participation status? Clinicians can now use an interactive tool on the CMS Quality Payment Program website to determine if they should participate in MIPS.**

Visit [qpp.cms.gov](http://qpp.cms.gov) > Check Now, enter your NPI and information will then be provided on whether or not you should participate in MIPS in 2017 and where to find resources.

CMS is encouraging physicians to sign up for the new CMS QPP listserv to stay up-to-date on new resources, upcoming milestones and deadlines, and CMS webinars on the QPP. To subscribe to the QPP listserv, go to [qpp.cms.gov](http://qpp.cms.gov) and select "Subscribe to Email Updates" at the bottom of the page.

### **ASCO is releasing a series of webinars to guide oncology practices to successful quality reporting:**

- June 19<sup>th</sup>—Quality Payment Program: Scoring for Advancing Care Information and Improvement Activities
- July 10<sup>th</sup>—Quality Payment Program: Optimizing your MIPS Score

All webinars are schedule for 1PM PT. Register at [www.asco.org/macra](http://www.asco.org/macra) > MACRA Webinar Series. ASCO has developed a MACRA decision tree tool to help oncology practices find precise information on their QPP participation status at [www.asco.org/practice-guidelines/billing-coding-reporting/macra-quality-payment-program/macra-practice-tools/determine-status](http://www.asco.org/practice-guidelines/billing-coding-reporting/macra-quality-payment-program/macra-practice-tools/determine-status). For more information and access to ASCO's revamped QPP/MACRA toolkit, educational materials, and resources, go to [www.asco.org/macra](http://www.asco.org/macra). ASH's updated MACRA webpage is at [www.hematology.org/Clinicians/7427.aspx](http://www.hematology.org/Clinicians/7427.aspx).

ANCO member practice manager Harvey Bichkoff has authored an ASCO *Connection* commentary entitled *An On-the-Ground Approach to Implementing MACRA in Your Practice*. Read

Bichkoff's commentary at [connection.asco.org/blogs](http://connection.asco.org/blogs).

**CMA's Center for Economic Services (CES) has published an update to its MACRA preparation checklist** entitled *MACRA: What Should I Do Now to Prepare?* available at [www.cmanet.org/macra](http://www.cmanet.org/macra).

**CMS has announced that it is now accepting hardship exceptions from the meaningful use requirements of the EHR incentive payment program for the 2016 reporting year.** Physicians who can show that demonstrating meaningful use would result in a significant hardship can apply for a one-year exception and avoid a negative payment adjustment in 2018. The deadline is July 1<sup>st</sup>. Go to [www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/PaymentAdj\\_Hardship.html](http://www.cms.gov/Regulations-and-Guidance/Legislation/EHRIncentivePrograms/PaymentAdj_Hardship.html) for more information and applications.

### **CMA, MOASC, and State Legislative & Regulatory Issues**

The *California Oncology Political Action Committee* (or CalCancerPAC), formed by ANCO and MOASC, supports candidates sensitive to the needs of hematologists/oncologists and people living with cancer in California. ANCO membership dues include a contribution to CalCancerPAC.

ANCO/MOASC-sponsored legislation entitled the *Oncology Clinical Pathway Act of 2017* (AB1107) would require health plans that choose to develop oncology clinical pathways to meet specific standards regarding those pathways and to divulge specific information to in-network providers upon request. Unfortunately, AB1107 did not pass out of the *Assembly Appropriations Committee* on May 30<sup>th</sup>.

**AB72, a new law that will change the billing practices of non-participating physicians providing non-emergent care at in-network**

**facilities, takes effect on July 1<sup>st</sup>.** The law, signed in 2016, is designed to reduce unexpected medical bills when patients go to an in-network facility but receive care from an out-of-network physician. CMA has published resources to help physicians navigate the new law, including an FAQ, instructions for obtaining patient consent, a sample consent form, and an overview of billing requirements under the new law. Visit [www.cmanet.org/ab-72](http://www.cmanet.org/ab-72) for more information.

### **Forthcoming CMA webinars include:**

- Transitioning your Practice: Retiring, Selling, or Buying a Practice (June 28)

Contact CMA's member help center at (800) 786-4262 or [memberservice@cmanet.org](mailto:memberservice@cmanet.org) for more information. Register online at [www.cmanet.org/events](http://www.cmanet.org/events).

*CMA Practice Resources* (CPR) is a monthly e-mail bulletin from CMA's *Center for Economic Services* that is full of tips and tools to help physicians and their office staff improve practice efficiency and viability. Subscribing to CPR is free and open to anyone, but CMA membership is necessary to access the resources, toolkits, forms, and tools that are located on the members-only CMA website. Please visit [www.cmanet.org/cpr](http://www.cmanet.org/cpr) to subscribe. The June 2017 edition includes:

- TRICARE transition to be delayed
- CMA urges CMS to address significant concerns with planned changes to ID cards
- Noridian deactivates more providers who failed to respond to revalidation requests
- Maintaining your Medicare opt-out status
- The Coding Corner: Why and how to perform coding self-audits

## **Noridian/JEMAC, DHCS/MediCal, & Private Payers**

*Noridian Administrative Services* is the **Jurisdiction E (JE) Medicare Administrative Contractor (MAC)**. Jurisdiction E includes California. Regularly review postings at the *Noridian/JEMAC* website at [med.noridianmedicare.com/web/jeb](http://med.noridianmedicare.com/web/jeb). Recent updates include:

- MLN Connects Provider eNews *Announcements*—EHR Incentive Programs: Submit Comments on Proposed Changes by June 13; New Quality Payment Program Resources Available; Review 2017 EHR Incentive Program Requirements *Claims, Pricers, and Codes*—July 2017 Average Sales Price Files Available *Publications*—Quality Payment Program Overview Web-Based Training Course-New; Scheduled End of the Intravenous Immune Globulin Demonstration MLN Matters Article-New
- Submitting Enrollment Applications Online-Learn How To Get Started!
- Recovery Auditor Region 4 Website and New Issues
- Diagnostic and Therapeutic Colonoscopy Final LCD-Effective July 17, 2017
- Claim Status Category and Claim Status Codes Update CR10043
- HCPCS Drug/Biological Code Changes-July 2017 CR10107

*Noridian/JEMAC's* Electronic Data Interchange Support Services (EDISS) invites you to subscribe to its e-mail distribution list to receive current information at [www.edissweb.com/cgp/news/index.html](http://www.edissweb.com/cgp/news/index.html).

**Forthcoming *Noridian/JEMAC* meetings/workshops include:**

- Understanding National and Local Coverage Determinations (June 13, 15, 20)
- Noridian Medicare Portal Registration and Functionality (June 14)

Visit [med.noridianmedicare.com/web/jeb/education/training-events](http://med.noridianmedicare.com/web/jeb/education/training-events) for more information and to register.

**Effective June 21<sup>st</sup>, providers must use the most recent version of the *Advance Beneficiary Notice of Noncoverage (ABN; Form CMS-R-131)*.** If the new form is not used on or after this date, any new ABN executed on the old form will be considered invalid and would result in provider liability if Medicare denies the claim. For more information, visit [www.cms.gov/Medicare/Medicare-General-Information/BNI/ABN.html](http://www.cms.gov/Medicare/Medicare-General-Information/BNI/ABN.html).

**The *Anthem Network Update*** (June 2017) is now available online at [www11.anthem.com/cal/provider/f5/s3/t3/pw\\_g311754.pdf](http://www11.anthem.com/cal/provider/f5/s3/t3/pw_g311754.pdf) and features articles entitled *Reminder: Prior authorization for Genetic Testing, Anthem Blue Cross will be expanding the Specialty Pharmacy prior authorization drug list, and Update to AIM diagnostic imaging clinical appropriateness guidelines*.

***UnitedHealthcare's Network Bulletin*** (June 2017) is now available online at [www.unitedhealthcareonline.com](http://www.unitedhealthcareonline.com) > Tools & Resources > News & Network Bulletin and features articles entitled *A new telemedicine policy; Colorectal cancer screening webinars; and, An important change to our network DME providers*.

### **EDUCATION**

*[Editor's Note: ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]*

#### ***ANCO's The State of Cancer Care***

ANCO's *ASCO Highlights* will not take place in 2017 in lieu of our encouragement of members to attend ASCO's *Best of ASCO* in San Francisco ([west-boa.asco.org](http://west-boa.asco.org); June 16-17<sup>th</sup>). However, ANCO will host an event on June 15<sup>th</sup> entitled

*The State of Cancer Care* with Margaret Tempero, M.D., and Wes Kidder, M.D., *University of California, San Francisco*, at the *San Francisco Marriott Marquis*. Download the meeting announcement/registration form at [www.anco-online.org/ANCOatBOA2017.pdf](http://www.anco-online.org/ANCOatBOA2017.pdf).

**SAVE THE DATE**  
**ANCO's 2017**  
**Professional Education Meeting**

ANCO will host its 2017 professional education meeting on September 6<sup>th</sup> at the *San José Fairmont*. The agenda will include *QPP/MACRA*, *ASCO's COME HOME Project*, *USP797/800*, and *California Legislative/Regulatory Updates*. Watch for a meeting announcement in early July.

**Additional Education Meetings**

June 13<sup>th</sup>

*For Caregivers: Practical Tips to Cope with Your Loved One's Lung Cancer (Part II of Living with Lung Cancer)*

CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

June 14<sup>th</sup>

*For Caregivers: Care Coordination for Your Loved One Living with Cancer and Other Health Problems (Part V of Life with Cancer: A Guide to Getting the Best Care)*

CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

June 14<sup>th</sup>

*Taking Your Pills on Schedule: The Importance of Adherence in the Treatment of Cancer*

CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

June 16-17<sup>th</sup>

*Best of ASCO*

ASCO

San Francisco

([boa.asco.org](http://boa.asco.org))

June 20<sup>th</sup>

*Advances in the Treatment of Metastatic Prostate Cancer (Part I of Living with Prostate Cancer)*

CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

June 21<sup>st</sup>

*Update on the Treatment of Bladder Cancer*  
CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

June 22<sup>nd</sup>

*Current Perspectives on Early Stage Breast Cancer*  
CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

June 26<sup>th</sup>

*Update in the Treatment of Colorectal Cancer*  
CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

June 27<sup>th</sup>

*For Caregivers: Coping with a Loved One's Prostate Cancer (Part II of Living with Prostate Cancer)*  
CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

June 29<sup>th</sup>

*What Are Generic Drugs: Understanding Their Role in Cancer Treatment—Current and Future Perspectives*

CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

June 29-30<sup>th</sup>

*POLST: It Starts with A Conversation*  
Coalition for Compassionate Care of California  
Long Beach  
([coalitionccc.org/training-events/polst-education/](http://coalitionccc.org/training-events/polst-education/))

June 30<sup>th</sup>

*Medical Update on Acute Myelogenous Leukemia (AML)*

CancerCare Connect Education Workshop  
([www.cancercare.org/connect\\_workshops](http://www.cancercare.org/connect_workshops))

July 14-15<sup>th</sup>

*16<sup>th</sup> Annual International Congress on the Future of Breast Cancer West*

Physicians' Education Resource

San Diego

(ANCO member discount code IBW17ANCO)

[www.gotoper.com/conferences/ibc/meetings/16th-annual-international-congress-on-the-future-of-breast-cancer](http://www.gotoper.com/conferences/ibc/meetings/16th-annual-international-congress-on-the-future-of-breast-cancer))

July 27-29<sup>th</sup>

18<sup>th</sup> Annual International Lung Cancer Congress

Physicians' Education Resource

Huntington Beach

(ANCO member discount code ILC17ANCO

[www.gotoper.com/conferences/ilc/meetings/](http://www.gotoper.com/conferences/ilc/meetings/)

18th-international-lung-cancer-congress)

Please contact the ANCO office for more information about these meetings.

## ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS

[Editor's Note: All ANCO members are also eligible for several tangible benefits.]

### Board of Directors

The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* teleconferences/meetings are open to individual physician members. The next regularly scheduled ANCO *Board of Directors* meeting is scheduled for June 21<sup>st</sup>.

Please call José Luis González, *ANCO Executive Director*, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

### Individual Member News

ASCO has endorsed Barbara McAneny, M.D., in her campaign for *President-Elect* of the *American Medical Association* (AMA). She is a medical oncologist/hematologist from New Mexico and would be the first oncologist elected to serve as *AMA President*. Dr. McAneny is an active ASCO volunteer who has served on the ASCO *Board of Directors* (2005-2008) and as a liaison to the *AMA House of Delegates* (2002-2013). She has also long been active in the AMA, and is past *Chair* and member of the *AMA Board of Trustees*. ANCO asks all members who are also AMA members to reach out to their AMA delegates and

encourage them to vote for Dr. McAneny for *President-Elect* at June 13<sup>th</sup>, 2017 election. For more information, visit [www.barbaramcaneny.com](http://www.barbaramcaneny.com).

**The ASCO Nominating Committee invites all ASCO members to recommend potential candidates for the ASCO Election for service beginning in June 2018.** Recommend your colleagues for open positions on the *Board of Directors* or *Nominating Committee* by visiting [www.asco.org/election](http://www.asco.org/election) through June 12<sup>th</sup>.

**A current *Directory of Members* is available online** at [www.anco-online.org/pubs.html](http://www.anco-online.org/pubs.html) as a .pdf document. We urge all ANCO members to download their own edition of *The ANCO Directory of Members*. Please verify your *Directory* entry and contact the ANCO office at [execdir@anco-online.org](mailto:execdir@anco-online.org) with any corrections, additions, and/or deletions.

### Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO *Board* believes that the *Association* and *The Permanente Medical Group* (TPMG) will each receive value from Group Membership.

ANCO initiated a **Multi Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks *Diablo Valley Oncology & Hematology Medical Group*, *EPIC Care*, *Marin Cancer Care*, *Pacific Cancer Care*, *Palo Alto Medical Foundation*, and *Valley Medical Oncology Consultants* for their multi site group memberships.

### Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching universities or research institutions are eligible for institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

### **Corporate Member News**

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

*AbbVie • Agendia • Alexion Pharmaceuticals  
AMGEN • ARIAD Pharmaceuticals  
Astellas Oncology • AstraZeneca  
Bayer Healthcare Pharmaceuticals  
bioTheranostics  
Boehringer Ingelheim Pharmaceuticals  
Bristol-Myers Squibb Oncology  
Cardinal Health Specialty Solutions  
Celgene • Clovis Oncology • Daiichi Sankyo  
Dendreon • Eisai • EMD Serono • Exelixis  
Foundation Medicine  
Genoptix Medical Laboratory  
GenPath Oncology • Genentech BioOncology  
Genomic Health • Gilead Sciences  
Guardant Health • Helsinn Oncology  
Heron Therapeutics • Incyte  
Infinity Pharmaceuticals  
Ipsen Biopharmaceuticals  
Janssen Oncology • Jazz Pharmaceuticals  
Kite Pharmaceuticals • Lilly Oncology •  
Merrimack Pharmaceuticals  
Medivation • Merck  
nanoString • Novartis Oncology  
Oncology Supply/ION • Pfizer Oncology  
Pfizer US Biosimilars • Pharmacyclics  
Sandoz Biopharmaceuticals • Sanofi Genzyme  
Seattle Genetics • Taiho Oncology  
Takeda Oncology • Tesaro • TEVA Oncology*

We especially wish to thank and welcome *Agendia, bioTheranostics, EMD Serono, Kite Pharmaceuticals, and Pfizer US Biosimilars* as new Corporate Members for 2017. Please visit [www.anco-online.org/assistance.html](http://www.anco-online.org/assistance.html) for **Corporate Member drug reimbursement and**

**patient assistance program information.** ANCO encourages all member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

*Foundation Medicine* informs ANCO that it and ASCO have announced an agreement to create efficiencies for research sites participating in ASCO's TAPUR Study in identifying potential participants for the study. Learn more at [www.asco.org/advocacy-policy/asco-in-action/asco-and-foundation-medicine-announce-collaboration-help-research](http://www.asco.org/advocacy-policy/asco-in-action/asco-and-foundation-medicine-announce-collaboration-help-research).

*Genentech BioOncology* will host an expert-led educational presentation entitled *Tecentriq in Locally Advanced or Metastatic Urothelial Carcinoma (mUC) and Previously Untreated Metastatic Non-small Cell Lung Cancer (NSCLC)* on Friday, June 16<sup>th</sup> at 6PM at *Fogo de Chao Brazilian Steakhouse*, San Francisco. RSVP at [www.medforcereg.net/SGEN8481](http://www.medforcereg.net/SGEN8481).

*Janssen Oncology* informs ANCO that Zytiga is now available in a new dosage (500mg) and formulation for patients with metastatic castration-resistant prostate cancer (mCRPC). In addition, *Janssen Oncology* will host a small interactive discussion entitled *Xarelto Pivotal Trials and Recently Published Real World Evidence in NVAf* on Friday, June 16<sup>th</sup> at 6:30PM, *One Market Restaurant*, San Francisco. RSVP at [www.medforcereg.net/SOMP116514](http://www.medforcereg.net/SOMP116514).

*Merck* informs ANCO that the *United States Food and Drug Administration* has approved Keytruda for the treatment of locally advanced or metastatic urothelial carcinoma (mUC) for first-line use in cisplatin-ineligible patients and second-line use post-platinum failure.

*Novartis Oncology* informs ANCO that the *United States Food and Drug Administration* has approved Zykadia for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

## Clinical Trial News

The NIH and FDA *Joint Leadership Council* have announced the release of the final clinical trial protocol template designed to increase protocol development efficiency, save time and money in medical product development, and help investigators develop more consistent, complete protocols. NIH simultaneously released an e-Protocol Writing Tool, recommended by ASCO, at [e-protocol.od.nih.gov/index.html#/home](http://e-protocol.od.nih.gov/index.html#/home).

**Stanford Cancer Center brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:**

- Intratumoral Injection of SD-101, an Immunostimulatory CpG, in combination with Ibrutinib and Local Radiation in Relapsed or Refractory Low-Grade Follicular Lymphoma [LYMNH10135; NCT02927964]. Principal Investigator: Ronald Levy, MD; Contact: Destiny Phillips, (650) 498-1313, [destinyph@stanford.edu](mailto:destinyph@stanford.edu)
- A Randomized Phase III Study Evaluating Modified FOLFIRINOX (mFFX) with or without Stereotactic Body Radiotherapy (SBRT) in the Treatment of Locally Advanced Pancreatic Cancer [PANC0015; NCT01926197]. Principal Investigator: Albert Koong, MD; Contact: Rachel Freiberg, (650) 7225-0438, [rachelf@stanford.edu](mailto:rachelf@stanford.edu)
- A Phase Ib Study Followed by an Open Label, Parallel, Randomized Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of GS-5829 in Combination with Exemestane or Fulvestrant Comparing with Exemestane or Fulvestrant Alone in Subjects with Advanced Estrogen Receptor Positive HER2-Breast Cancer [BRS0069; NCT02983604]. Principal Investigator: Suleiman Massarweh, M.D.; Contact: Karen Lau, (650) 723-0658; [kkwlau@stanford.edu](mailto:kkwlau@stanford.edu)
- A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Lung Cancer, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-Administration of Platinum Based Doublet Regimens [QUADRUPLE THREAT; LUN0084; NCT02489903]. Principal Investigator: Sukhmani Padda, M.D.; Contact: Melanie San Pedro-Salcedo, (650) 724-1388; [msanpedro@stanford.edu](mailto:msanpedro@stanford.edu)
- A Phase Ib/II Trial of Hu5F9-G4 in Combination with Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma [LYMNH10139; NCT02953509]. Principal Investigator: Ranjana Adavani, M.D.; Contact: Sipra Choudhury, (650) 736-2563; [schoudhury@stanford.edu](mailto:schoudhury@stanford.edu)
- A Phase I Study of bb2121 in BCMA-Expressing Multiple Myeloma [HEMMLY0025; NCT02658929]. Principal Investigator: Michaela Liedtke, M.D.; Contact: Reneth Tien, (650) 723-0646; [rtien@stanford.edu](mailto:rtien@stanford.edu)
- A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age [HEMMLY0021; NCT01208662]. Principal Investigator: Michaela Liedtke, M.D.; Contact: Reneth Tien, (650) 723-0646; [rtien@stanford.edu](mailto:rtien@stanford.edu)
- An Open-label, Multicenter Phase I Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia [HEMMDS0034; NCT02841540]. Principal Investigator: Peter Greenberg, M.D.; Contact: Savita Kamble, (650) 723-8594; [skamble@stanford.edu](mailto:skamble@stanford.edu)
- 68Ga-PSMA PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy in Patients with Elevated PSA [PROS0076; NCT02673151]. Principal Investigator: Andrei Iagaru, M.D.; Contact: Jordan Cisneros, (650) 725-6409; [jordan.cisneros@stanford.edu](mailto:jordan.cisneros@stanford.edu)

Further information is available at [cancer.stanford.edu/trials/](http://cancer.stanford.edu/trials/).

**UC San Francisco brings the following oncology clinical trials (not previously listed or changed) to the attention of the ANCO membership:**

- Lifestyle and Outcomes after Gastro-Intestinal Cancer: A Prospective Cohort Study (LOGIC; CC#154520). Contact: Andrea Bocobo, (415) 476-3755, [logicstudy@ucsf.edu](mailto:logicstudy@ucsf.edu)
- Survivor Choices for Eating and Drinking (Succeed)—Colorectal Cancer (CC#164511). Contact: Andrea Bocobo, (415) 476-3755, [succeedstudy@ucsf.edu](mailto:succeedstudy@ucsf.edu)



- Phase I Study of TAS-102 (Lonsurf) and Radioembolization with 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases (CC#16452). Contact: Maddy Griffith, (415) 476-7974, [madeline.griffith@ucsf.edu](mailto:madeline.griffith@ucsf.edu)
- A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Gene Fusions or other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy (CC#15452). Contact: Maddy Griffith, (415) 476-7974, [madeline.griffith@ucsf.edu](mailto:madeline.griffith@ucsf.edu)
- A Phase II Study of PEGPH20, Gemcitabine Plus Nap-Paclitaxel in Patients With Upfront or Borderline Resectable Pancreatic Cancer (CC#144515). Contact: Louis Wong, (415) 514-8101, [louis.wong@ucsf.edu](mailto:louis.wong@ucsf.edu)
- A Phase I Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer (CC#169517). Contact: Phu Lam, (415) 514-6363; [phu.lam@ucsf.edu](mailto:phu.lam@ucsf.edu)
- A Dose-Finding Phase 1 Study of TAS-120 in Patients With Advanced Solid Tumors With or Without Fibroblast Growth Factor/Receptor (FGF/FGFR)-Related Abnormalities followed by a Phase 2 Study in Patients with Advanced Solid Tumors with FGF/FGFR-Related Abnormalities (CC#17457). Contact: Maddy Griffith, (415) 476-7974; [madeline.griffith@ucsf.edu](mailto:madeline.griffith@ucsf.edu)
- A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (MORPHEUS-Pancreatic Cancer; CC#175612). Contact: Jennifer Luan, (415) 514-6220; [jennifer.luan@ucsf.edu](mailto:jennifer.luan@ucsf.edu)
- Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial; CC#174513). Contact: Jennifer Luan, (415) 514-6220; [jennifer.luan@ucsf.edu](mailto:jennifer.luan@ucsf.edu)
- A Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer (CC#174517). Contact: Jennifer Luan, (415) 514-6220; [jennifer.luan@ucsf.edu](mailto:jennifer.luan@ucsf.edu)

Further information is available at [cancer.ucsf.edu/trials](http://cancer.ucsf.edu/trials).

### **Publications, Resources, Services, & Surveys**

ANCO encourages all members to participate in ASCO's *Practice Census*, the only annual survey of the entire oncology community that aims to capture and describe changes in cancer care and oncology practice over time. Be counted by going to [apps.asco.org/oncology-practice-central/survey](http://apps.asco.org/oncology-practice-central/survey).

**The ASCO Guidelines App is your go-to tool for implementing guideline recommendations into practice.** This user-friendly app provides health care providers, patients, and caregivers with the recommended cancer care options for a variety of cancer types. It also includes interactive tools to inform treatment decisions at the point of care, thus increasing the quality of care provided to patients. The app is free to members and nonmembers, kept up to date and will continue to grow as more guidelines and tools are added. Download the app at [www.asco.org/guidelines](http://www.asco.org/guidelines) or [www.asco.org/apps](http://www.asco.org/apps).

ASCO and the *College of American Pathologists (CAP)* invite comment on their evidence-based guideline for human epidermal growth factor receptor 2 (HER2) testing in breast cancer. For more information, visit [www.asco.org/advocacy-policy/asco-in-action/asco-and-cap-invite-comment-focused-update-her2-testing-guideline](http://www.asco.org/advocacy-policy/asco-in-action/asco-and-cap-invite-comment-focused-update-her2-testing-guideline).

ASCO's *Clinical Affairs Department* is dedicated to providing services, education, and resources to support oncology practices. It offers hands-on assistance in areas such as practice management, quality care assessment and improvement, and efficiency and business intelligence to meet the needs and demands of the current oncology landscape. Resources on the business of oncology, practice management (staffing, technology), practice transformation, and market analysis are available from the *Department*. For more information, visit [www.asco.org/practice-guidelines/practice-support](http://www.asco.org/practice-guidelines/practice-support).

**A new Care Delivery Review in the *Journal of Oncology Practice* evaluates and summarizes current published research that addresses the need for early and continuous Advanced Care Planning (ACP) in oncology care.** Through this research review, successful interventions and barriers in the literature are identified, as well as suggestions to implement these interventions on a larger scale, while also identifying gaps in the current literature to help guide future research in ACP. Read the full article at [ascopubs.org/doi/abs/10.1200/JOP.2017.021246?journalCode=jop](http://ascopubs.org/doi/abs/10.1200/JOP.2017.021246?journalCode=jop).

**ASCO and *Innovative Oncology Business Solutions (IOBS)* have announced a new collaboration, ASCO COME HOME—an oncology medical home program designed to transition community oncology practices from volume-based to value-based care by structuring reimbursement around the full range of services needed by patients with cancer.** ASCO COME HOME will also prepare oncology practices for full implementation of the Quality Payment Program under MACRA and will be available across the country starting on January 1<sup>st</sup>, 2017. ASCO is now recruiting practices for the fee-based 2017 ASCO COME HOME program. For more information, please visit [www.asco.org/advocacy-policy/asco-in-action/asco-come-home-here-offering-direct-support-practices-transitioning](http://www.asco.org/advocacy-policy/asco-in-action/asco-come-home-here-offering-direct-support-practices-transitioning).

**In 2017, practices will also be able to use the QOPI platform to meet the MIPS reporting requirement of one measure through manual reporting.** While one measure is the minimum requirement to avoid the 2019 penalty, ASCO encourages all practices to report on at least four measures to become fully acquainted with the system and ensure that the CMS requirements are met. For more information, please visit [www.asco.org/practice-guidelines/billing-coding-reporting/macra-quality-payment-program/macra-resources](http://www.asco.org/practice-guidelines/billing-coding-reporting/macra-quality-payment-program/macra-resources).

**ASH is now accepting nominations for members to participate in its 7<sup>th</sup> annual *Advocacy Leadership***

***Institute*** taking place September 27-28<sup>th</sup> in Washington, D.C. This two-day workshop is an opportunity for ASH members who wish to learn about legislation and health policy affecting hematology research and practice. Nominations are being accepted through June 16<sup>th</sup>. Learn more at [www.hematology.org/Advocacy/ALI.aspx](http://www.hematology.org/Advocacy/ALI.aspx).

**NCCN has published and/or updated their *Chemotherapy Order Templates, Clinical Practice Guidelines in Oncology, Drugs & Biologics Compendium, Evidence Blocks, Guidelines for Patients, Imaging Appropriate Use Criteria, and/or Radiation Therapy Compendium*** for acute lymphoblastic leukemia (V1.2017), bladder cancer (V5.2017), bone cancer (V2.2017), breast cancer (Stage III, V1.2017), breast cancer screening and diagnosis (V1.2017), chronic lymphocytic leukemia/small lymphocytic lymphoma (V2.2017), diffuse large B-cell lymphoma (V3.2017), esophageal and esophagogastric junction cancers (V1.2017), follicular lymphoma (V3.2017), genetic/familial high-risk assessment: colorectal (V1.2017), head and neck cancers (AUC, V2.2017), hepatobiliary cancers (V2.2017), kidney cancer (V1.2017), palliative care (V2.2017), thyroid carcinoma (AUC, V2.2017). Go to [www.nccn.org](http://www.nccn.org) for more information. NCCN is pleased to offer pocket-sized versions of the NCCN *Clinical Practice Guidelines in Oncology* for a number of their guidelines at [www.nccn.org/redirects/nicelines.asp?Type=general](http://www.nccn.org/redirects/nicelines.asp?Type=general).

### ***Individual Membership Dues for 2017***

**Final notices of membership renewal for 2017 were mailed in early May.** If you have not yet done so, then please return your 2017 membership dues to ANCO now to ensure your inclusion in *The ANCO Directory of Members*. Be sure to provide ANCO with your e-mail address and the name(s) and e-mail address(es) of office and/or nurse manager contact(s). Those not renewing their membership by June 30<sup>th</sup> will be deleted from the *Directory of Members*, and will no longer be eligible for any ANCO benefits.